Attached files
| file | filename |
|---|---|
| EX-10.3 - SETTLEMENT AGREEMENT, DATED JANUARY 1, 2018, BETWEEN DELMAR PHARMACEUTICALS, INC - Kintara Therapeutics, Inc. | f10q1217ex10-3_delmarpharma.htm |
| EX-32.1 - CERTIFICATION - Kintara Therapeutics, Inc. | f10q1217ex32-1_delmarpharma.htm |
| EX-31.2 - CERTIFICATION - Kintara Therapeutics, Inc. | f10q1217ex31-2_delmarpharma.htm |
| EX-31.1 - CERTIFICATION - Kintara Therapeutics, Inc. | f10q1217ex31-1_delmarpharma.htm |
| EX-10.4 - DELMAR PHARMACEUTICALS, INC. 2017 OMNIBUS EQUITY INCENTIVE PLAN (AS AMENDED AND - Kintara Therapeutics, Inc. | f10q1217ex10-4_delmarpharma.htm |
| 10-Q - QUARTERLY REPORT - Kintara Therapeutics, Inc. | f10q1217_delmarpharmaceutic.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of DelMar Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended December 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Scott Praill, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: February 14, 2018
| /s/ Scott Praill | |
| Scott Praill | |
| Chief Financial Officer (Principal Financial Officer) |